To include your compound in the COVID-19 Resource Center, submit it here.

Mero licenses AAT deficiency candidate from AstraZeneca

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Mereo BioPharma Group plc (LSE:MPH) an

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE